research use only
Cat.No.E1107
|
In vitro |
DMSO
: 69 mg/mL
(200.73 mM)
Ethanol : 17 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 343.73 | Formula | C16H13ClF3NO2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 451491-47-7 | -- | Storage of Stock Solutions |
|
|
Read more about storage stability stock solution CAS number SMILES
| In vitro |
CTB effectively induces apoptosis, up-regulates the expression of P300, and increases the acetylation and total P53 protein levels in MCF-7 cells. |
|---|---|
| In vivo |
CTB combinated with CpG, and aluminum hydroxide playsa synergistic effect to enhance ClfA221-550-induced immune responses, which possesses the potential to develop a novel vaccine to prevent infection of S. aureus. |
References |
|
(data from https://clinicaltrials.gov, updated on 2025-12-18)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07292636 | NOT_YET_RECRUITING | CLASS II DIVISION 1 MALOCCLUSION; Class II Malocclusion; Growth; Overjet; Class II Buccal Segment Relationship; Class II Growth Modification; Distalization; Oral Health-Related Quality of Life |
Aslam Alkadhimi |
2026-03 | |
| NCT05433181 | Not yet recruiting | SARS-CoV-2 |
University of Pennsylvania |
2025-02 | Phase 1|Phase 2 |
| NCT06593054 | COMPLETED | Healthy |
Pfizer |
2024-07-29 | PHASE1 |
| NCT06344559 | Not yet recruiting | Healthy |
Rutgers The State University of New Jersey |
2024-05-01 | Not Applicable |
| NCT06347055 | Not yet recruiting | Nicotine Dependence |
University of Missouri-Columbia |
2024-04-15 | Not Applicable |
| NCT06301334 | Not yet recruiting | Pain Mangement of Thoracotomy |
Sohag University |
2024-03-01 | Not Applicable |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.